tirzepatide easo update

tirzepatide easo update

Stop Prescribing Semaglutide - Tirzepatide Is Proven?

In 2025, the EASO Commission positioned tirzepatide as the preferred first-line GLP-1 agent, citing superior weight-loss outcomes over semaglutide. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. tirzepatide EASO update Key Takeaways * Tirzepatide